Like pls_老虎社区_美港股上老虎

shanshan88
2021-11-08

Like pls

FDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment

Eton Pharmaceuticals Inc and Azurity Pharmaceuticals Inc have announced that the FDA has approved Ep

FDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":844055971,"tweetId":"844055971","gmtCreate":1636379888297,"gmtModify":1636380382936,"author":{"id":3577599976368524,"idStr":"3577599976368524","authorId":3577599976368524,"authorIdStr":"3577599976368524","name":"shanshan88","avatar":"https://static.tigerbbs.com/f1ad40f03dfd5bc695854371a0ca9c29","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844055971","repostId":1156155834,"repostType":4,"repost":{"id":"1156155834","kind":"news","pubTimestamp":1636379472,"share":"https://www.laohu8.com/m/news/1156155834?lang=&edition=full","pubTime":"2021-11-08 21:51","market":"us","language":"en","title":"FDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1156155834","media":"Benzinga","summary":"Eton Pharmaceuticals Inc and Azurity Pharmaceuticals Inc have announced that the FDA has approved Ep","content":"<ul>\n <li><b>Eton Pharmaceuticals Inc</b>&nbsp;and&nbsp;<b>Azurity Pharmaceuticals Inc</b>&nbsp;have announced that the&nbsp;FDA has approved Eprontia (topiramate) oral solution, 25mg/mL.</li>\n <li>Eprontia has been approved as a monotherapy for partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older.</li>\n <li>The drug has also been approved as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as a preventive treatment of migraine in patients 12 years of age and older.</li>\n <li>Eprontia is the first oral liquid formulation of topiramate to be approved by the FDA.</li>\n <li>Azurity will be responsible for commercializing the product, and it anticipates product availability by the end of 2021.</li>\n <li>Eton will receive a $5 million milestone payment upon Eprontia's commercial launch, a royalty on net sales, and potential commercial milestones.</li>\n <li><b>Price Action:</b>&nbsp;ETON shares are down 3.66% at $6.06&nbsp;during the premarket session on the last check Monday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Eton's Formulated Topiramate For Seizure, Migraine Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-08 21:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/11/23950419/fda-approves-etons-formulated-topiramate-for-seizure-migraine-treatment><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eton Pharmaceuticals Inc and Azurity Pharmaceuticals Inc have announced that the FDA has approved Eprontia (topiramate) oral solution, 25mg/mL.\nEprontia has been approved as a monotherapy for partial-...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/11/23950419/fda-approves-etons-formulated-topiramate-for-seizure-migraine-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETON":"Eton Pharmaceuticals, Inc."},"source_url":"https://www.benzinga.com/general/biotech/21/11/23950419/fda-approves-etons-formulated-topiramate-for-seizure-migraine-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156155834","content_text":"Eton Pharmaceuticals Inc and Azurity Pharmaceuticals Inc have announced that the FDA has approved Eprontia (topiramate) oral solution, 25mg/mL.\nEprontia has been approved as a monotherapy for partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older.\nThe drug has also been approved as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older; and as a preventive treatment of migraine in patients 12 years of age and older.\nEprontia is the first oral liquid formulation of topiramate to be approved by the FDA.\nAzurity will be responsible for commercializing the product, and it anticipates product availability by the end of 2021.\nEton will receive a $5 million milestone payment upon Eprontia's commercial launch, a royalty on net sales, and potential commercial milestones.\nPrice Action: ETON shares are down 3.66% at $6.06 during the premarket session on the last check Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":717,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}